Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
1 finding from 1 review
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Secondary hemorrhage at any time point · people with traumatic hyphema
Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: systemic hypotension · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic tranexamic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with control (moderate certainty).
1 finding from 1 review
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary hemorrhage at any time point · people with traumatic hyphema
Systemic tranexamic acid may leads to lower secondary hemorrhage at any time point compared with control (low certainty).
1 finding from 1 review
Nausea · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review